Merck KGaA Rebounds After COVID-19 Lockdowns
Mavenclad And Fertility Business Back On Track
Executive Summary
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.